Regeneron, US75886F1075

Regeneron stock: EU approves flexible Libtayo dosing

Published on 11/17/2026 at 14:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Regeneron stock gains a new EU dosing milestone for Libtayo. A US regulatory decision on the same regimen is expected in March 2027.

EU approval broadens Libtayo options

  • The European Commission approved a 700 mg Libtayo dose every six weeks after an initial 12-week treatment phase.
  • Eligible patients may receive subsequent 350 mg infusions in 15 to 30 minutes after a well-tolerated 30-minute infusion.
  • A US supplemental application remains under review, with a decision expected in March 2027.
Regeneron, US75886F1075, Illustration mit AI erstellt.

On Tuesday, November 17, 2026, Regeneron Pharmaceuticals said the European Commission approved a flexible dosing schedule for Libtayo, its cemiplimab-based cancer treatment. The Regeneron release published by GlobeNewswire said the approval covers all six of Libtayo's approved European Union cancer indications.

Regeneron stock traded at 863.30 euros on Lang & Schwarz at 14:10 CET on Tuesday, November 17. The quote reflects the company's US-listed equity in a euro-denominated trading venue.

Flexible schedule expands treatment choice

The approval lets patients receive 700 mg of Libtayo every six weeks after completing an initial 12 weeks of treatment with 350 mg administered every three weeks. Each infusion in the initial phase is given intravenously over 30 minutes, while the extended dose is also infused over 30 minutes.

The European decision also allows subsequent 350 mg infusions to take between 15 and 30 minutes when the patient's first 30-minute infusion was well tolerated. Regeneron said the revised schedule is intended to reduce the burden of frequent clinic visits and lengthy infusions while giving healthcare providers more flexibility.

The approved uses span cutaneous squamous cell carcinoma, including adjuvant treatment for patients at high risk of recurrence, basal cell carcinoma after treatment with a hedgehog pathway inhibitor, and several non-small cell lung cancer settings. The authorization also covers recurrent or metastatic cervical cancer after progression on or following platinum-based chemotherapy.

US review remains the next milestone

Regeneron said the European approval is supported by safety and efficacy findings from the Libtayo clinical development program together with pharmacokinetic and pharmacodynamic modeling and simulation. The company is pursuing the same alternative dosing regimen in the United States, where a supplemental Biologics License Application remains under review by the Food and Drug Administration. A decision is expected in March 2027.

For investors, the EU decision broadens the administration options for an established oncology product and adds a regulatory milestone to Regeneron's cancer portfolio. The release also said Libtayo serves as a backbone for investigational combinations across the company's oncology pipeline, which spans more than 30 types of solid tumors and blood cancers.

Regeneron Pharmaceuticals

  • ISIN: US75886F1075
  • WKN: 881535
  • US ticker: REGN
  • Primary exchange: Nasdaq
  • Lang & Schwarz quote: 863.30 euros, Tuesday, November 17, 2026, at 14:10 CET

The S&P 500 is the relevant broader-market reference for US-listed Regeneron.

More news and analyses on Regeneron stock

Disclaimer...
en | US75886F1075 | REGENERON | boerse | 70527112 | bgmi